NOT.F - Novartis AG

Frankfurt - Frankfurt Delayed Price. Currency in EUR
80.16
0.00 (0.00%)
At close: 7:57PM CEST
Stock chart is not supported by your current browser
Previous Close80.16
Open0.00
Bid80.11 x 30000
Ask80.34 x 30000
Day's Range0.00 - 0.00
52 Week Range
Volume1,589
Avg. Volume151
Market Cap178.982B
Beta (3Y Monthly)0.24
PE Ratio (TTM)16.47
EPS (TTM)4.87
Earnings DateN/A
Forward Dividend & Yield2.51 (3.13%)
Ex-Dividend Date2019-03-04
1y Target EstN/A
  • Reuters

    China expands drug bulk-buy programme, puts pressure on pharma firms

    China has expanded a pilot drug bulk-buying programme to almost the entire country in an attempt to negotiate lower prices from drug manufacturers, heaping fresh pressure on multinational pharmaceutical companies and their domestic rivals. The programme rolled out last year saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process to bulk-buy 25 types of drugs. The drugs on the list include off-patent blockbusters that are made by Western pharmaceutical giants, but which have generics made by local players, such as Eli Lilly's cancer treatment drug Pemetrexed, which is sold under the brand name Alimta, and leukaemia therapy Imatinib sold by Novartis as Gleevec.

  • The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation
    Benzinga

    The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...

  • Novartis takes aim at Roche's star MS drug
    Reuters

    Novartis takes aim at Roche's star MS drug

    Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.

  • Reuters

    UPDATE 2-Novartis takes aim at Roche's star MS drug

    Swiss drugmaker Novartis on Friday stepped up its challenge to Roche's multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its cross-town rival's drug Ocrevus. Novartis said ofatumumab, already approved as Arzerra to treat leukaemia, reduced annual relapses better than Sanofi's Aubagio in two head-to-head late-stage studies against relapsing forms of MS (RMS). Detailed study results are due at an MS conference in Sweden next month.

  • 5 Companies Still Run by Families
    Motley Fool

    5 Companies Still Run by Families

    In a world of large, faceless corporations, it can sometimes be nice to think of family values in business. What are the biggest family-owned businesses around?

  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • Novartis to answer U.S. Senate demand for data manipulation details
    Reuters

    Novartis to answer U.S. Senate demand for data manipulation details

    Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval. Novartis, which won approval for Zolgensma in May -- more than a month before it told the Food and Drug Administration of the alleged data fraud -- has terminated several scientists amid an internal investigation.

  • Novartis executive sold shares before drug data manipulation made public
    Reuters

    Novartis executive sold shares before drug data manipulation made public

    An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from tests of its gene therapy Zolgensma had been manipulated. Novartis announced the stock sale by an executive member of the board of directors or a member of the executive committee in a Swiss stock exchange filing dated July 19. The sale was made after the company had informed the FDA about the data manipulation but before the FDA announced it publically on Aug 6.

  • Motley Fool

    A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis

    What Novartis' misstep means to investors, plus how Exact Sciences is trying to lock up the genetic testing market.

  • Reuters

    Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.

  • Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data
    Investor's Business Daily

    Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data

    Swiss pharma giant Novartis reportedly fired two scientists at its AveXis unit for manipulating data necessary to gain approval of gene therapy Zolgensma, CNBC reported Wednesday.

  • Reuters

    UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.

  • Barrons.com

    Everyone’s Mad At Novartis. But the Stock Is Doing Just Fine

    Public pressure is heating up on Novartis A.G. over how the company handled a data manipulation issue, but the stock is doing just fine, thanks.

  • Novartis names Bulto as new head of U.S. drugs business
    Reuters

    Novartis names Bulto as new head of U.S. drugs business

    Swiss drugmaker Novartis has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept. 1. The statement said Chouraqui had "consistently demonstrated strong leadership, ethics and integrity" during his tenure. Bulto, who will report to Marie France Tschudin, global president of Novartis Pharmaceuticals, is a 14-year company veteran who has worked across every therapeutic area at the group and helped launch several products, including top-selling inflammation drug Cosentyx in the U.S. market.

  • 5 Biggest New Drugs Approved in 2019 So Far
    Motley Fool

    5 Biggest New Drugs Approved in 2019 So Far

    And the one big pharma most likely to benefit the most.

  • Reuters

    UPDATE 1-Senator Grassley seeks info on Novartis's Zolgensma data issues

    U.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its $2 million gene therapy, Zolgensma, by Aug. 23. The Republican, in a letter dated Aug.9 to the drugmaker's Chief Executive Officer Vasant Narasimhan, asked the company to provide all records on its internal inquiry into Zolgensma data discrepancies. Grassley wanted Novartis to submit additional details, including the date when it came to know that it issued manipulated data to the FDA as well as the number of employees terminated in relation to the issue.

  • Reuters

    Senator Grassley seeks info on Novartis's Zolgensma data issues

    U.S. Senate Finance Committee Chairman Chuck Grassley has sought more information from Swiss drugmaker Novartis AG on the reasons for "intentional withholding" of data related to its $2 million gene therapy, Zolgensma, by Aug. 23. In a letter dated Aug.9 to the drugmaker's Chief Executive Officer Vasant Narasimhan, Republican Grassley asked the company to provide all records on its internal inquiry into Zolgensma data manipulation https://www.grassley.senate.gov/sites/default/files/constituents/2019-08-09%20CEG%20to%20Novartis%20(Misconduct).pdf. The drugmaker had last week said it knew about the discrepancies in data it submitted to regulators while it sought approval of its gene therapy, but delayed notifying authorities until it has completed an internal investigation.

  • TheStreet.com

    [video]Amgen Climbs After Winning Patent Case on Enbrel

    Shares of Amgen were rising nearly 5% Monday after the drugmaker won a patent case against rival Novartis over its highly anticipated rheumatoid arthritis treatment Enbrel. Amgen's Enbrel patents likely will be protected until 2029.

  • Amgen wins U.S. patent battle on arthritis drug Enbrel
    Yahoo Finance Video

    Amgen wins U.S. patent battle on arthritis drug Enbrel

    A U.S. Judge up-held 2 patents relating to Amgen’s Rheumatoid Arthritis drug Enbrel after they were challenged by competitor Novartis. Yahoo Finance's Scott Gamm joins Akiko Fujita to discuss.